Minerva Neurosciences (NERV) Times Interest Earned (2014)
Minerva Neurosciences' (NERV) quarterly Times Interest Earned came in at -$1.02 in Q1 2026, up 73.88% on a QoQ basis from -$3.92 in Q4 2025.
Analysis
Minerva Neurosciences (NERV) Times Interest Earned (2014) Analysis & Trends
Minerva Neurosciences (NERV) has 14 years of Times Interest Earned data on file, last reported at -$1.02 in Q1 2026.
- Quarterly Times Interest Earned changed N/A year-over-year to -$1.02 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.71 (changed N/A YoY) and the FY2025 annual result came in at -$0.15, up 33.38% from the prior year.
- Times Interest Earned rose to -$1.02 in Q1 2026, from -$3.92 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$0.05 in Q4 2024 to a low of -$369.27 in Q2 2024.
- A 5-year average of -$52.66 and a median of -$3.08 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2022 — Times Interest Earned surged 78.09% — and 2024, when it plunged 16419.07%.
- Tracing NERV's Times Interest Earned over 5 years: stood at -$0.06 in 2022, then plunged by 31.6% to -$0.07 in 2023, then jumped by 36.41% to -$0.05 in 2024, then slumped by 8231.74% to -$3.92 in 2025, then soared by 73.88% to -$1.02 in 2026.
- The last three Times Interest Earned figures came in at -$1.02 (Q1 2026), -$3.92 (Q4 2025), and -$0.05 (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - | - |